Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C: A randomised, controlled pilot study

Swiss Medical Weekly

Volumn 137, Issue 29-30, 2007, Pages 418-423

  Wenger, Christa ^a   Bischof, Thomas ^a   Gonvers, Jean Jacques ^b   Renner, Eberhard L ^c   Mullhaupt, Beat ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Amantadine; Drug therapy; Hepatitis C; Human study; Triple therapy

Indexed keywords

ALPHA2B INTERFERON; ALPHAN3 INTERFERON; AMANTADINE; AMANTADINE SULFATE; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; IRRITABILITY; LEUKOPENIA; LIVER CIRRHOSIS; MAJOR DEPRESSION; MALE; MONOTHERAPY; MOOD CHANGE; NEUROLOGIC DISEASE; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE;

EID: 34547587347     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitic C in the United States. N Engl J Med. 1992;327:1899-905.
2. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17-35.
3. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-6.
4. McHutchison JG, Gordon SC, Schiff ER, Shiffmann ML, Lee WM, Rustigi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as inital treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-92.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Internation hepatitis interventional therapy group. Lancet. 1998;352:1426-32.
6. Heathcote EJ, Shiftman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-80.
7. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-72.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiftman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marines G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
11. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology. 2001;33:231-40.
12. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA. 2001;285:193-9.
13. Camma C, Bruno S, Schepis F, Lo Iacono O, Andreone P, Gramenzi AG, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut. 2002;51:864-9.
14. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology. 2002;36:S128-34.
15. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci. 1997;42:1681-7.
16. Tabone M, Ercole E, Zaffino C, Sallio Bruno F, Pera A, Bonino F. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol. 1998;30:611-3.
17. Senturk H, Mert A, Akdogan M, Tabak F, Basaran G, Turkoglu S, et al. Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b. Scand J Infect Dis. 2000;32:575-6.
18. Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol. 2004;40:478-83.
19. Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol. 2004;41:462-73.
20. Gaeta GB, Stornaiuolo G, Stanzione M, Ascione T, Pasquazzi C, Taliani G, et al. Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. J Viral Hepat. 2001;8:284-6.
21. Khalili M, Denham C, Perrillo R. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. Am J Gastroenterol. 2000;95:1284-9.
22. Teuber G, Berg T, Naumann U, Raedle J, Brinkmann S, Hopf U, et al. Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. J Viral Hepat. 2001;8:276-83.
23. Younossi ZM, Mullen KD, Zakko W, Hodnick S, Brand E, Barnes DS, et al. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. J Hepatol. 2001;34:128-33.
24. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon non-responsive chronic hepatitis C. Hepatology. 2000;32:630-4.
25. Adinolfi LE, Utili R, Tonziello A, Ruggiero G. Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. Gut. 2003;52:701-5.
26. Berg T, Naumann U, Wiedenmann B, Hopf U. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Z Gastroenterol. 2001;39:145-51.
27. Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol. 1999;31:130-4.
28. Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F, et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol. 2003;39:606-13.
29. Piai G, Rocco P, Tartaglione MT, Ciarleglio A, Focareta R, Grimaldi E, et al. Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients. Hepatol Res. 2003;25:355-63.